IN-PERSON SYMPOSIA
Thursday, Nov. 11
AstraZeneca
Thursday, Nov. 11, 2021
12:15-1:15 p.m.
Room 202AB, WEWCC
Treatment Options in Lung Cancer: Unresectable Stage III NSCLC & Extensive-Stage SCLC
Treatment of Unresectable Stage III NSCLC and Extensive-Stage SCLC presented by Dr Leora Horn, MD, MSc, FRCPC, Global Clinical Head for Lung Cancer and Lung Cancer Strategy at AstraZeneca.
IsoPlexis
Thursday, Nov. 11, 2021
12:15-1:15 p.m.
Room 204ABC, WEWCC
Emerging standard single cell functional biomarkers of immune function and potency , and Duomic, a novel simultaneous single cell transcriptomics and functional proteomics platform to transform connected therapeutic biology
Akoya Biosciences
Thursday, Nov. 11, 2021
6:30-8 p.m.
Independence Ballroom, Marriott Marquis
Leading and Managing Spatial Biomarker Innovations in Immuno-Oncology: Multi-Stakeholder Perspectives
Advances in the field of spatial biomarkers in Immuno-Oncology are accelerating the pathway to precision medicine. Join us for a Dinner Symposium at SITC on Thursday, November 11th at 6-8pm sponsored by Akoya Biosciences. An expert panel from Pharma, Academia, and the CRO space will discuss how they are transforming this field through innovation and its impact on the spatial biomarker landscape. In this panel discussion, Drs. Robert Schreiber (Washington University School of Medicine in St. Louis), Michael Surace (AstraZeneca), and Qingyan (Sandy) Au (NeoGenomics) will discuss their current research and initiatives that establish the vital role of spatial biomarkers in setting the future direction for achieving Precision Immuno-Oncology.
Learning Objectives:
- Understand the current landscape including market trends and stakeholder needs for spatial biomarkers in immuno-oncology.
- Learn about the various strategies and solutions posed by different research segments including Pharma, Academia, and CRO industry to advance spatial biomarkers.
- Gain insight into the role of spatial signatures in improving immunotherapy outcomes in the future.
Exelixis, Inc.
Thursday, Nov. 11, 2021
6:30-8 p.m.
Georgetown, Marriott Marquis
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
This session provides an overview of a combination treatment approach for patients with advanced renal cell carcinoma. The overview will cover efficacy and safety data, tolerability, patient-reported quality of life and dosing considerations.
Palleon Pharmaceuticals
Thursday, Nov. 11, 2021
6:30-8 p.m.
Gallaudet, Marriott Marquis
Sialoglycan-Mediated Immune Regulation: Glycobiology Meets Immuno-Oncology
Speakers include:
- Carolyn Bertozzi, Ph.D., Anne T. and Robert M. Bass Professor of Chemistry at Stanford University, Baker Family Director of Stanford CHEM-H, Scientific Co-Founder, Palleon Pharmaceuticals
- James Paulson, Ph.D., Cecil H. and Ida M. Green Professor and Co-Chair, Department of Molecular Medicine, Professor, Department of Immunology and Microbiology, Scripps Research Institute, Scientific Advisor, Palleon Pharmaceuticals
- David Feltquate, M.D., Ph.D., Chief Medical Officer, Palleon Pharmaceuticals
Please join us in person or virtually for a discussion of recent discoveries that highlight the connection between glycoscience and immuno-oncology.
Please register: : https://us02web.zoom.us/webinar/register/WN_mYlgxKr_Qe23N3-pHwhm3g
Friday, Nov. 12
10x Genomics
Friday, Nov. 12, 2021
1:30-2:30 p.m.
Exhibit Hall Stage, WEWCC
Driving biomarker discovery in cancer immunotherapy with single cell and spatial multiomics
The vast complexities of cancer are characterized by heterogeneity - from intrinsic features of the tumor to complex interactions with the tumor microenvironment. Elucidating disease mechanisms and response to immunotherapies requires a deep understanding of the cell types and functional states mediating the anti-tumor immune response, as well as their spatial organization in tissue. However, traditional assays and tools that analyze tissue in bulk miss significant amounts of information and context due to limited throughput and/or resolution. Through innovations in single cell sequencing and spatial multiomics, solutions from 10x Genomics help researchers dissect the immune and tumor microenvironment, track the anti-tumor immune response, and uncover mechanisms of response and resistance to immunotherapies. Join 10x Genomics to learn how researchers are using our single cell assays and spatial biology tools to gain a multidimensional view of cancer.
Adaptive Biotechnologies
Friday, Nov. 12, 2021
1:30-2:30 p.m.
Independence Ballroom, Marriott Marquis
Utilizing immunosequencing in cancer research and immunotherapy
Adaptive Biotechnologies’ immunoSEQ® Technology is an end-to-end immunosequencing solution capable of profiling millions of B- and T-cell receptors at high throughput and providing a quantitative view into the immune repertoire.
Join or watch our Symposium titled: Utilizing immunosequencing in cancer research and immunotherapy
Presented by Dr. Katie Boland, DVM, Ph.D., with guest speakers Dr. Kellie N. Smith, Ph.D. and Dr. Theodore Scott Nowicki, M.D., Ph.D. to learn about:
- The principles behind the immunoSEQ Technology (Dr. Boland)
- Using immunoSEQ in the solid tumor setting (Dr. Smith)
- Addressing epigenetic suppression and optimizing therapies with immunosequencing (Dr. Nowicki)
Oncocyte
Friday, Nov. 12, 2021
6:30-8 p.m.
Independence Ballroom, Marriott Marquis
DetermalO: A Novel Predictive Biomarker that Assesses the Tumor Microenvironment to Identify Responders to Immunotherapy. RCT Clinical Trial Data Demonstrating Significantly Improved Outcomes in Biomarker Positive Population
Speakers: Michael Hurwitz, Jason Porter, Naoto Ueno, Gregory Vidal
Description: As immune checkpoint inhibitors become more prevalent across many cancer types, there is a need for a better biomarker to better predict response and ensure the right patient is receiving the right therapy. During our discussion, we will highlight new developments in the immunotherapy treatment landscape and the role of predictive biomarkers to accurately select therapy. We will present data generated by DetermaIO™ in over 900 patients across multiple tumor types (NSCLC, TNBC, bladder and kidney cancer) that demonstrated the test’s ability to consistently identify both responders and non-responders to immune checkpoint inhibitor therapies, as well as identify potential responders missed by existing biomarkers. A panel Q&A and interactive discussion will focus on the applications of DetermaIO in the clinical setting and in next-generation IO biopharma clinical trials. Please join us for dinner and an exciting discussion on the future of predictive biomarkers for immunotherapy.